November 21st, 2023 ProAlt’s therapeutic project named ‘METASTCURE' that has obtained the ‘Seal of Excellence’ label within the Accelerator program of the European Innovation Council has been selected by the Community of Madrid for direct-grant support. The excellence, impact and remarkable potential for success of METASCURE project made it eligible to receive a substantial grant [...]
January 27th, 2023 The collaborative project named ‘Preclinical development and evolution of second-generation antibodies for the treatment of metastatic colorectal cancer’ has been selected to receive funding in the joint ISCIII-CDTI call for proposals in innovation linked to ‘Personalized Medicine and Advanced Therapies’. The multidisciplinary research consortium involves strategic partners like the Group of Mechanisms [...]
The project named CANCERKINE and title ‘Preclinical development of monoclonal antibodies against IL13Ra2 for cancer therapy’ has been selected to receive funding from the Ministry of Science and Innovation. The aim of CANCERKINE is the preclinical development of the anti-IL13Ra2 monoclonal antibody 5.5.4 and their by-products in order to further advance this biological therapeutic product [...]
January 14th, 2021 Tres Cantos, Madrid, Spain. Protein Alternatives (PROALT), a leading company in the development of therapeutic monoclonal antibodies in oncology, has been selected as one of the two companies that will receive funding from the R&D and innovation programme of Madrid Region during 2021 and 2022. MetastCure project, with title “Preclinical evaluation of [...]
November 25th, 2020 PROALT’s project proposal named ‘METASTCURE – Anti cadherin-RGD monoclonal antibody PA-0661 for the treatment of metastatic colorectal cancer’ has received the Seal of Excellence recognition from the Enhanced European Innovation Council (EIC) pilot in EU. The EIC Accelerator programme is part of the Enhanced European Innovation Council pilot and provides grant and blended [...]
23rd, April 2019 Protein Alternatives S.L. (PROALT) has begun the clinical validation study of its blood-based diagnostic test for colorectal cancer in Luminex® and ELISA-based formats. COLODETECT® test is based on detecting in blood the autoantibodies (AAbs) generated by the human body against proteins related to the colorectal cancer tumor, known as tumor-associated antigens [...]
10th, June 2016 PROALT has been selected by Enterprise Europe Network (EEN) as a successfully funded company and invited to present its ColoDetect project in the European Commission's booth #5977 at BIO International Convention trade fair. The event, hold in San Francisco (United States), took place on Wednesday 8 June 2016. PROALT presented the key [...]
1st, April 2016 ColoDetect project announces the launch of its website. ColoDetect is a project funded by the European Union through the H2020 SME Instrument Phase 2 and developed by Protein Alternatives (PROALT). The project started in October 2015 and will run for three years. Its objective is the development and commercialization of a blood-based [...]
October 1st, 2015 COLODETECT, a proposal submitted by the Spanish biotechnology company PROALT, has been selected to receive EU funding from H2020 SME Instrument. In total, the Commission received 580 project proposals from European SMEs by the first cut-off date of the so-called Horizon 2020’s SME Instrument Phase 2. PROALT is the only Spanish company [...]
May 6th, 2015 The 'Innovators' supplement of the 'El Mundo' newspaper, one of the most widely distributed journals in Spain, has interviewed Dr Juan Ignacio Imbaud, R&D Director of the biotech company Protein Alternatives (Madrid, Spain). The reason was the recent approval of the project named COLODETECT, which was presented by the company to the [...]
Copyright ©2020 Protein Alternatives SL. All rights reserved | Legal Notice & Privacy Policy
